Financials in USD. Standardized financial statements.
A compact view of how BioLife Sciences Inc. turns revenue into operating income and net income.
| Metric | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $411,695 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $1.40M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $13,008 |
| Gross Profit? | -$985,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$13,008 |
| Gross Margin? | -239.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $259,160 | $0 | $42,284 | $329,131 | $12,500 | $21,155 | $10,700 | $7,305 | $124,428 | $58,685 |
| Operating Income? | -$1.24M | $0 | -$42,280 | -$329,000 | -$12,500 | -$21,160 | -$10,700 | -$7,305 | -$124,000 | -$71,693 |
| EBITDA? | -$1.22M | $171,860 | -$42,284 | -$329,000 | -$12,500 | -$21,155 | -$10,700 | -$7,305 | -$124,000 | -$280,000 |
| Income Before Tax | -$1.27M | -$1,134 | -$52,715 | -$340,000 | -$19,175 | -$28,880 | -$10,700 | -$31,230 | -$202,000 | -$293,000 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$1.27M | -$1,134 | -$52,715 | -$340,000 | -$19,175 | -$28,880 | -$10,700 | -$31,230 | -$202,000 | -$293,000 |
| EPS? | $-0.02 | $-0.00 | $-0.00 | $-0.08 | $-0.05 | $-0.07 | $-0.03 | $-0.08 | $-0.75 | $-2.25 |
| Diluted EPS? | $-0.02 | $-0.00 | $-0.00 | $-0.08 | $-0.05 | $-0.07 | $-0.03 | $-0.08 | $-0.29 | $-2.25 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality